Sugi Predict

Sugi Predict / Compounds / SCHEMBL1592500

SCHEMBL1592500

SCHEMBL1592500

CC(C)(C)c1ccc(N2C(c3ccc4[nH]c([C@@H]5CCCN5)nc4c3)CCC2c2ccc3[nH]c([C@@H]4CCCN4)nc3c2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN10A Q9Y5Y9 2/20 0.61
▸ PARP1 P09874 2/20 0.35
▸ CDC7 O00311 4/20 0.35
▸ CCNE1 P24864 4/20 0.35
▸ CDK2 P24941 4/20 0.35
▸ ROCK1 Q13464 4/20 0.35
▸ DBF4 Q9UBU7 4/20 0.35
▸ ALDH1A1 P00352 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ CCNC P24863 1/20 0.32
▸ CDK8 P49336 1/20 0.32
▸ CLK1 P49759 1/20 0.32
▸ DAPK1 P53355 1/20 0.32
▸ CDK3 Q00526 1/20 0.32
▸ DMPK Q09013 1/20 0.32
▸ DYRK1A Q13627 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3265964 1.00 SCN10A (0.61) SCN10APARP1CDC7CCNE1CDK2
SCHEMBL2756437 1.00 SCN10A (0.61) SCN10APARP1CDC7CCNE1CDK2
SCHEMBL1592503 1.00 SCN10A (0.61) SCN10APARP1CDC7CCNE1CDK2
SCHEMBL12684516 0.94 SCN10A (0.55) SCN10APARP1CDC7CCNE1CDK2
SCHEMBL15458266 0.93 SCN10A (0.53) SCN10APARP1CDC7CCNE1CDK2
SCHEMBL15457856 0.92 SCN10A (0.52) SCN10APARP1CDC7CCNE1CDK2
SCHEMBL240766 0.92 SCN10A (0.71) SCN10AALDH1A1LMNAMAPTHTT
SCHEMBL18653106 0.89 SCN10A (0.49) SCN10ACDC7CCNE1CDK2ROCK1
SCHEMBL1982263 0.87 SCN10A (0.47) SCN10A
SCHEMBL1982269 0.87 SCN10A (0.47) SCN10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230285378-A1 Anti-Viral Compounds ABBVIE INC. (US) 2023-09-14 — — US disclosed
US-20230285378-A1 Anti-Viral Compounds ABBVIE INC. (US) 2023-09-14 — — US disclosed
US-20230285378-A1 Anti-Viral Compounds ABBVIE INC. (US) 2023-09-14 — — US disclosed
EP-3438106-A1 ANTI-VIRAL COMPOUNDS AbbVie Ireland Unlimited Company (IE) 2019-02-06 — — EP disclosed
US-20190015402-A1 Anti-Viral Compounds ABBVIE INC. (US) 2019-01-17 — — US disclosed
US-10039754-B2 Anti-viral compounds ABBVIE INC. (US) 2018-08-07 — — US disclosed
US-10039754-B2 Anti-viral compounds ABBVIE INC. (US) 2018-08-07 — — US disclosed
US-10028937-B2 Anti-viral compounds ABBVIE INC. (US) 2018-07-24 — — US disclosed
US-10028937-B2 Anti-viral compounds ABBVIE INC. (US) 2018-07-24 — — US disclosed
US-20170157105-A1 Anti-Viral Compounds ABBVIE INC. (US) 2017-06-08 — — US disclosed
US-20120220562-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2012-08-30 — — US disclosed
EP-2455376-A1 Heterocyclic compounds as inhibitors of hepatitis C virus (HCV) Abbott Laboratories (US) 2012-05-23 — — EP disclosed
US-20120004196-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2012-01-05 — — US disclosed
US-20120004196-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2012-01-05 — — US disclosed
EP-2368890-A1 Hepatitis C virus inhibitors Abbott Laboratories (US) 2011-09-28 — — EP disclosed
US-20110207699-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2011-08-25 — — US disclosed
US-20110207699-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2011-08-25 — — US disclosed
US-20110092415-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2011-04-21 — — US disclosed
US-20110092415-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2011-04-21 — — US disclosed
US-20110092415-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2011-04-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10028937-B2 Anti-viral compounds HAVCR2, EIF2AK2, MAVS SCN10A 4583/4885PARP1 2308/4885CDC7 905/4885
US-20230285378-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS SCN10A 4583/4885PARP1 2308/4885CDC7 905/4885
US-20120220562-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS SCN10A 4583/4885PARP1 2308/4885CDC7 905/4885
US-20170157105-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS SCN10A 4583/4885PARP1 2308/4885CDC7 905/4885
US-20110092415-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS SCN10A 4583/4885PARP1 2308/4885CDC7 905/4885
US-20110207699-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS SCN10A 4583/4885PARP1 2308/4885CDC7 905/4885
US-20190015402-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS SCN10A 4583/4885PARP1 2308/4885CDC7 905/4885
US-20120004196-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS SCN10A 4583/4885PARP1 2308/4885CDC7 905/4885
US-10039754-B2 Anti-viral compounds HAVCR2, EIF2AK2, MAVS SCN10A 4583/4885PARP1 2308/4885CDC7 905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.